Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer

被引：0
|
作者：
Federica Marmorino
Lisa Salvatore
Cecilia Barbara
Giacomo Allegrini
Lorenzo Antonuzzo
Gianluca Masi
Fotios Loupakis
Beatrice Borelli
Silvana Chiara
Maria Chiara Banzi
Emanuela Miraglio
Domenico Amoroso
Francesco Dargenio
Andrea Bonetti
Angelo Martignetti
Myriam Paris
Daniela Tomcikova
Luca Boni
Alfredo Falcone
Chiara Cremolini
机构：
[1] Azienda Ospedaliero-Universitaria Pisana,Department of Medical Oncology
[2] Ospedale Civile di Livorno,Division of Medical Oncology
[3] Pontedera Hospital,Department of Oncology
[4] Azienda Ospedaliero-Universitaria Careggi,undefined
[5] Istituto Oncologico Venoto,undefined
[6] National Institute for Cancer Research,undefined
[7] Arcispedale Santa Maria Nuova,undefined
[8] IRCCS,undefined
[9] S. Croce General Hospital,undefined
[10] Ospedale Versilia–Lido di Camaiore,undefined
[11] Dipartimento oncologico AUSL 6 Livorno–Piombino,undefined
[12] Department of Medical Oncology Mater Salutis Hospital Legnago,undefined
[13] Dipartimento Oncologico AUSL 7,undefined
[14] S.O.C. Oncologia–Ospedale degli Infermi,undefined
[15] Fondazione Sandro Pitigliani,undefined
[16] Clinical Trial Coordinating Center,undefined
[17] AOU Careggi,undefined
[18] Istituto Toscano Tumori,undefined
来源：
British Journal of Cancer | 2017年 / 116卷
关键词：
bevacizumab beyond progression; LDH; predictive marker;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：318 / 323
页数：5
相关论文
共 50 条
  • [31] Clinical benefit of bevacizumab in responding and non-responding patients with metastatic colorectal cancer
    Mass, R.
    Sarkar, S.
    Holden, S. N.
    Hurwitz, H. I.
    EJC SUPPLEMENTS, 2005, 3 (02): : 182 - 182
  • [32] Retrospective cohort study on the safety and efficacy of bevacizumab for metastatic colorectal cancer patients: The HGCSG0801study-Analysis of bevacizumab beyond progression (BBP).
    Fukushima, Hiraku
    Yuki, Satoshi
    Kobayashi, Yoshimitsu
    Hatanaka, Kazuteru
    Kusumi, Takaya
    Hosokawa, Ayumu
    Miyagishima, Takuto
    Takeuchi, Satoshi
    Kudo, Mineo
    Komatsu, Yoshito
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [33] 2nd line bevacizumab(BEV) continuation chemotherapy(Cx) beyond early progression for metastatic colorectal cancer(mCRC)
    Komoda, Masato
    Yamamoto, Shun
    Kawakami, Takeshi
    Mitani, Seiichiro
    Tsuji, Yasushi
    Izawa, Naoki
    Kawakami, Kentaro
    Yamamoto, Yoshiyuki
    Makiyama, Akitaka
    Yamazaki, Kentaro
    Masuishi, Toshiki
    Esaki, Taito
    Tsuda, Takashi
    Okuda, Hiroyuki
    Moriwaki, Toshikazu
    Boku, Narikazu
    ANNALS OF ONCOLOGY, 2019, 30 : 100 - 100
  • [34] Bevacizumab adds survival benefit in colorectal cancer
    Susman, E
    LANCET ONCOLOGY, 2005, 6 (03): : 136 - 136
  • [35] Effect of continuation of bevacizumab following disease progression in patients with metastatic colorectal cancer on survival
    Samelis, G. F.
    Tsiakou, A.
    Karamanidi, M.
    Pelechrini, M.
    Zaganides, A.
    Ekmektzoglou, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [36] Monitoring the effects of bevacizumab beyond progression in murine colorectal cancer: a functional imaging approach
    Heijmen, L.
    Punt, C. J. A.
    ter Voert, E. E. G. W.
    de Geus-Oei, L.
    Heerschap, A.
    Bussink, J.
    Zerbi, V.
    Oyen, W.
    Span, P. N.
    Boerman, O.
    van Laarhoven, H. W. M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2012, 39 : S259 - S259
  • [37] BEVACIZUMAB plus CHEMOTHERAPY BEYOND FIRST PROGRESSION IN METASTATIC COLORECTAL CANCER PATIENTS PREVIOUSLY TREATED WITH BEVACIZUMAB-BASED THERAPY: TML STUDY SUBGROUP FINDINGS
    Andre, Thierry
    Jose Maria, Vieitez
    Bouche, Olivier
    Bennouna, Jaafar
    Sastre, Javier
    Alonso-Orduna, Vicente
    Arnold, Dirk
    Osterlund, Pia
    Greil, Richard
    Van Cutsem, Eric
    von Moos, Roger
    Reyes-Rivera, Irmarie
    Makrutzki, Martina
    Kubicka, Stefan
    ANNALS OF ONCOLOGY, 2012, 23 : 14 - 14
  • [38] The Clinical Benefit of Bevacizumab in Metastatic Colorectal Cancer Is Independent of K-ras Mutation Status: Analysis of a Phase III Study of Bevacizumab with Chemotherapy in Previously Untreated Metastatic Colorectal Cancer
    Hurwitz, Herbert I.
    Yi, Jing
    Ince, Bwilliam
    Novotny, William F.
    Rosen, Oliver
    ONCOLOGIST, 2009, 14 (01): : 22 - 28
  • [39] Effectiveness of bevacizumab (BV) beyond disease progression in metastatic colorectal cancer (mCRC): Analyses by sex in the ARIES observational cohort study (OCS)
    Cohn, Allen Lee
    Hurwitz, Herbert
    Bekaii-Saab, Tanios S.
    Bendell, Johanna C.
    Kozloff, Mark
    Tezcan, Haluk
    Flick, Elizabeth Dawn
    Mun, Yong
    Fish, Susan
    Dalal, Darshan
    Grothey, Axel
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [40] Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial
    Masi, G.
    Salyatore, L.
    Boni, L.
    Loupakis, F.
    Cremolini, C.
    Fornaro, L.
    Schirripa, M.
    Cupini, S.
    Barbara, C.
    Safina, V.
    Granetto, C.
    Fea, E.
    Antonuzzo, L.
    Boni, C.
    Allegrini, G.
    Chiara, S.
    Amoroso, D.
    Bonetti, A.
    Falcone, A.
    ANNALS OF ONCOLOGY, 2015, 26 (04) : 724 - 730
12345